Teclistamab for Waldenstrom's macroglobulinemia
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This study tests a new drug called teclistamab for people with Waldenstrom's macroglobulinemia (WM) that has come back or not responded to earlier treatments. The drug is designed to help your immune system attack the cancer cells. The study aims to see if it is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a diagnosis of Waldenstrom's macroglobulinemia and need treatment for it.
- Your disease must have returned or not responded after at least one previous treatment, which should have included a targeted therapy like a BTK inhibitor or a rituximab-based regimen.
- You should have received a BTK inhibitor before, unless you couldn't due to medical reasons.
- If you have symptoms of thick blood (like nosebleeds, headaches, blurred vision), you must have a procedure called plasmapheresis before starting treatment.
- You must be 18 years or older and be able to take care of yourself (ECOG performance status 0-2).
- You must have adequate organ function, such as acceptable blood cell counts, kidney and liver function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests epcoritamab, an immunotherapy that helps your immune system attack cancer cells, for people with Waldenstrom macroglobulinemia (WM) whose disease has gotten worse or who couldn't tolerate previous treatments. It's for those who've already tried a BTK inhibitor (like ibrutinib or zanubrutinib) and an anti-CD20 antibody (like rituximab).
This trial tests a combination of three drugs (pirtobrutinib, venetoclax, and rituximab) for people newly diagnosed with Waldenstrom's macroglobulinemia who have not had treatment before and need therapy for their symptoms.
This trial tests a combination of three drugs (zanubrutinib, bendamustine, and rituximab) for people with Waldenstrom macroglobulinemia who have not been treated before. The goal is to see if this combination is safe and effective.
This trial tests a combination of two drugs—mosunetuzumab and pirtobrutinib—in patients whose Waldenstrom macroglobulinemia (a rare blood cancer) has returned or stopped responding to prior treatment. The study aims to see if this combination can shrink tumors and help patients feel better.
This trial tests a new drug called teclistamab for people with AL amyloidosis whose disease has not responded well to previous treatments. It aims to see if the drug can help control the disease.
This trial tests a combination of three drugs (nemtabrutinib, bortezomib, and rituximab) for people with Waldenstrom's macroglobulinemia (a rare blood cancer) who have not yet had treatment. It aims to see if the combination is safe and effective.
Hear when a new Waldenstrom's Macroglobulinemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.